Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Myeloid 2Other hematologic neoplasm 1Genitourinary 1Gastrointestinal 1

Conditions

Lung Neoplasms 2

Interventions

Carboplatin 191pembrolizumab 155Pemetrexed 134Cisplatin 117durvalumab 71Paclitaxel 71osimertinib 67Nivolumab 66Docetaxel 63Specimen Handling 61atezolizumab 57Magnetic Resonance Spectroscopy 50Etoposide 46Gemcitabine 42Radiotherapy 39Radiosurgery 37130-nm albumin-bound paclitaxel 34Drug Therapy 30Cetuximab 28Bevacizumab 27Ipilimumab 25Taxes 23cemiplimab 22tislelizumab 20Platinum 20amivantamab 18Radiation 18Immunoglobulin G 171,2-diaminocyclohexaneplatinum II citrate 17Disulfides 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
canakinumab × Thoracic × 90 days × Clear all
NCT06038526 2026-05-20

Evaluation of Canakinumab in High-Risk Former-Smokers

Ohio State University Comprehensive Cancer Center

Phase 2 Active not recruiting
41 enrolled
Thoracic

Lung Neoplasms

NCT04789681 2026-04-16

Canakinumab for the Prevention of Lung Cancer, the Can-Prevent-Lung Trial

M.D. Anderson Cancer Center

Phase 2 Recruiting
50 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡